Publications and press
Peer-reviewed research from our team on patient-derived models, high-throughput response measurement and clinically relevant discovery — plus recent coverage of the company.
Publications
A Clinically Relevant High-Throughput Phenotypic Parameter for Drug Discovery
Presents NOGR, a growth-rate-based metric tailored for brightfield imaging of patient-derived tumour organoids, improving the accuracy of cytostatic and cytotoxic drug response assessment.
Functional Organoid Screening Enables Discovery of Synergistic Combination Therapies in Oncology
Computational approaches for understanding cancer mechanisms and developing targeted therapeutic strategies through advanced data analysis.
Novel Methodologies for Patient-Derived Drug Screening
Detailed protocols for organoid-based high-throughput screening, including innovative approaches to experimental assay design.
Corneal Endothelial Regeneration
Investigates innovative approaches to corneal endothelial regeneration and therapeutic strategies for restoring endothelial function.
Retrospective Analysis of Clinical Correlation Using Patient-Derived Organoids
Explores the clinical predictive value of patient-derived organoids by correlating their drug response profiles with patient outcomes in pancreatic cancer.
In the press
Belgian techbio Sightera raises €3M to teach AI from extreme patient biology
Coverage of Sightera's funding round to scale patient-derived organoid screening and train AI on response data from treatment-resistant disease.
Jong geweld: Maxim Le Compte — “De ultieme droom is een kankertherapie ontwikkelen met onze eerste ontdekkingen”
Sightera featured in the Belgian Financial Times, explaining how a patient-centric discovery approach is used to design innovative cancer therapies.
Sightera Biosciences — Innovating Drug Discovery
Coverage of Sightera's approach to drug discovery and the company's development within the University of Antwerp science park ecosystem.